Search

everythinglearnresearchcommunity

for

Search:↓

There's a growing resistance to the antibiotic mupirocin in children's skin infections caused by MRSA in New York.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Etanercept may not prevent alopecia areata from coming back.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Ixekizumab effectively treats generalized pustular psoriasis.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.

Etanercept may cause lichen planopilaris, so doctors should be cautious.

Upadacitinib improved multiple immune-related conditions in one patient.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Advanced nanocarrier and microneedle drug delivery methods are more effective, safer, and less invasive for treating skin diseases.

An imbalance between certain immune cells is linked to a chronic skin condition and may be influenced by obesity, smoking, and autoimmune issues.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.